AmberGen receives US Patent 8,114,587 for analyzing DNA mutations in fecal samples for colorectal cancer detection
/in News, PIONEERING NEW TECHNOLOGIES /by Kenneth RothschildAgreement between AmberGen and SomaLogic® enables use of photocleavable reagent in SOMAmer® technology used to discover new biomarkers
/in MAKING A DIFFERENCE, News /by Kenneth RothschildAmberGen awarded Phase I SBIR grant for use of photocleavable peptide and peptoid bead-libraries in screening biomolecular interactions
/in News /by Kenneth RothschildAmberGen receives US Patent 7,897,335 for electrophoresis-free methods of high sensitivity detection of chain truncation mutations using tagged translated nascent proteins
/in News, PIONEERING NEW TECHNOLOGIES /by Kenneth RothschildAmberGen wins Illumina’s VeraCode™ Assay Design Challenge for development of a multiplex colorectal cancer diagnostic
/in MAKING A DIFFERENCE, News /by Kenneth RothschildPromega distributes AmberGen’s fluorescent tRNA based protein engineering technology
/in MAKING A DIFFERENCE, News /by Kenneth RothschildThermo-Fisher sells AmberGen’s PC-Biotin-NHS reagent
/in MAKING A DIFFERENCE, News /by Kenneth RothschildGlen Research distributes AmberGen’s Photocleavable Phosphoramidite DNA-labeling reagents
/in MAKING A DIFFERENCE, News /by Kenneth RothschildLink Technologies Ltd. offers AmberGen’s Photocleavable Phosphoramidite DNA-labeling reagents in Europe
/in MAKING A DIFFERENCE, News /by Kenneth RothschildRecent News
Recent Posts
- AmberGen receives US Patent 9,910,034 increasing its broad coverage on PC-PURE™ photo-affinity biomarker purification and enrichment technology for improving the accuracy of diagnostic testing March 2018
- Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™) February 2018